PF-04691502

DB11974InvestigationalSmall molecule

PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₂H₂₇N₅O₄ · 425.4809 g/mol (avg)
Code names: PF 04691502 · PF-4691502

Resolves to

Compound

UNII4W39NS61KICAS1013101-36-4ChEMBLCHEMBL1234354PubChem25033539

Structure

InChIKeyXDLYKKIQACFMJG-WKILWMFISA-NSMILESCOC1=CC=C(C=N1)C1=CC2=C(C)N=C(N)N=C2N([C@H]2CC[C@@H](CC2)OCCO)C1=O

Targets

P42345MTORP48736PIK3CG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-04691502, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account